Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + LCRT for TNT in Locally Advanced Rectal Cancer
NCT07527026Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in rectal cancer, sponsored by Chinese PLA General Hospital. Started Feb 2026; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07527026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527026.